Pentoxifylline and skin inflammation
- 1 July 1998
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 23 (4), 168-172
- https://doi.org/10.1046/j.1365-2230.1998.00316.x
Abstract
Cyclic nucleotide phosphodiesterase inhibitors, such as pentoxifylline, have been shown to beneficially influence a large number of inflammatory skin diseases. The biological effects of pentoxifylline on the production of proinflammatory cytokines, leukocyte–endothelial cell adhesion, chemokines and leukocyte–keratinocyte adhesion in skin inflammation are discussed.Keywords
This publication has 50 references indexed in Scilit:
- Is pentoxifylline effective in the treatment of psoriasis?Journal of the American Academy of Dermatology, 1996
- Effects of Pentoxifylline on the Adherence of Polymorphonuclear Neutrophils to Oxidant-Stimulated Human Endothelial CellsJournal of Cardiovascular Pharmacology, 1995
- Is pentoxifylline the drug of the decade?Journal of the American Academy of Dermatology, 1994
- PentoxifyllineJournal of the American Academy of Dermatology, 1994
- In vitro immunomodulatory effects of pentoxifyllineImmunology Letters, 1993
- In vitro modulation of normal and diseased human neutrophil function by pentoxifyllineBlut: Zeitschrift für die Gesamte Blutforschung, 1990
- Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.The Journal of Experimental Medicine, 1990
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortalityLife Sciences, 1989
- Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofyllineBiochemical and Biophysical Research Communications, 1988